Under a tenth of people eligible to benefit from weight-loss injections like Wegovy are able to get them, warns the global health agency as it releases its inaugural guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key obstacles to universal availability to the injections that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Shortage
Even in the current best projected case, the supply of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, per the health organization.
The guideline encourages countries and companies to expand access, by measures such as licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of a leading brand – is set to lapse in multiple countries in 2026.
How Obesity Drugs Work
The injections imitate a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so people reduce food intake.
Individuals usually start to lose weight within a few weeks of beginning the once-weekly jabs.
Research indicates users may regain a significant portion a year later of discontinuing the drug, because their normal hunger resume.
To be overweight or obese raises your likelihood for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
